Literature DB >> 30221906

Evaluation of physiologic and abnormal glucose uptake in palatine tonsils: differential diagnostics with sequential dual-time-point 2-deoxy-2-[18F]FDG PET/CT.

Agata K Pietrzak1, Joanna Kazmierska2, Andrzej Marszalek3, Witold Cholewinski2.   

Abstract

BACKGROUND: The aim of this article was to evaluate the usefulness of sequential dual-time-point 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (DTP [18F]FDG PET/CT) in distinguishing physiologic, inflammatory and malignant palatine tonsils as difficult to differentiate in the oncological practice.
METHODS: A total of 90 patients before the treatment underwent sequential DTP [18F]FDG PET/CT examinations. We analyzed 104 structures in 90 patients: 31 physiologic tonsils, 28 histopathologically confirmed inflammatory tonsils of non-specified origin, 31 histopathologically confirmed palatine tonsils cancer and 14 non-malignant contralateral tonsils in patients with histopathologically confirmed unilateral palatine tonsil malignancy. Patients underwent sequential [18F]FDG PET/CT examinations at 60 and 90 minutes post-injection of the [18F]FDG. We analyzed the SUVmax and SUVmean values at 60 and 90 minutes post-injection changes over time and the Retention Index (RI-SUVmax). To find the predictive SUV value and the RI cut-off between physiology, inflammatory and malignancy, we used the ROC analysis.
RESULTS: The average SUVmax values at 60 and 90minutes post-injection within physiologic palatine tonsils were 1.36±0.26 and 1.31±0.26, respectively, P>0.05. The average SUVmax values at 60 and 90 minutes post-injection within inflammatory and malignant tonsils were 3.74±1.45, 3.80±1.47 (P>0.05) and 5.19±2.19, 5.81±2.50 (P<0.05), respectively. The RI-SUVmax fluctuation over time were 5±28% within physiologic, -4±11% within contralateral non-malignant tonsils in patients with one tonsil involved, 2±11% within inflammatory and 13±13% within malignant tonsils.
CONCLUSIONS: The sequential dual-time-point [18F]FDG PET/CT examinations may increase the sensitivity and the specificity of the PET/CT method in differential palatine tonsils diagnosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30221906     DOI: 10.23736/S1824-4785.18.03065-0

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  4 in total

1.  Comparison of Volumetric Quantitative PET Parameters Before and After a CT-Based Elastic Deformation on Dual-Time 18FDG-PET/CT Images: A Feasibility Study in a Perspective of Radiotherapy Planning in Head and Neck Cancer.

Authors:  Meriem Maajem; Jean-Christophe Leclère; David Bourhis; Valentin Tissot; Nicolas Icard; Laëtitia Arnaud; Romain Le Pennec; Gurvan Dissaux; Dorothy M Gujral; Pierre-Yves Salaün; Ulrike Schick; Ronan Abgral
Journal:  Front Med (Lausanne)       Date:  2022-02-11

2.  Reproducibility of Standardized Uptake Values Including Volume Metrics Between TOF-PET-MR and TOF-PET-CT.

Authors:  Aruki Tanaka; Tetsuro Sekine; Edwin E G W Ter Voert; Konstantinos G Zeimpekis; Gaspar Delso; Felipe de Galiza Barbosa; Geoffrey Warnock; Shin-Ichiro Kumita; Patrick Veit Haibach; Martin Huellner
Journal:  Front Med (Lausanne)       Date:  2022-03-02

3.  Differentiation Between Malignant and Benign Pulmonary Nodules by Using Automated Three-Dimensional High-Resolution Representation Learning With Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography.

Authors:  Yung-Chi Lai; Kuo-Chen Wu; Neng-Chuan Tseng; Yi-Jin Chen; Chao-Jen Chang; Kuo-Yang Yen; Chia-Hung Kao
Journal:  Front Med (Lausanne)       Date:  2022-03-18

4.  The value of diffusion kurtosis imaging, diffusion weighted imaging and 18F-FDG PET for differentiating benign and malignant solitary pulmonary lesions and predicting pathological grading.

Authors:  Ziqiang Li; Yu Luo; Han Jiang; Nan Meng; Zhun Huang; Pengyang Feng; Ting Fang; Fangfang Fu; Xiaochen Li; Yan Bai; Wei Wei; Yang Yang; Jianmin Yuan; Jianjian Cheng; Meiyun Wang
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.